Press Releases

Tumor-directed N17350 and systemically delivered N17465 are based on the breakthrough discovery of a novel innate immune mechanism of action, which activates cell death pathways specific to cancer cells New preclinical data demonstrate direct and tumor-selective efficacy of N17350 in both chemotherapy-naïve and -experienced ovarian cancer patient cells and cell-derived xenograft (CDX) models  First data…

SAN DIEGO, March 6, 2024 – Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel innate immune mechanism of action, announced today it will unveil preclinical data on systemically delivered N17465 in an oral presentation and new preclinical data for tumor-directed N17350 in a poster presentation at the American Association for…

SAN DIEGO, November 3, 2023 – Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel mechanism of action, announced the presentation of new preclinical data for N17350 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held virtually and at the San Diego Convention Center from November 1-5,…

SAN DIEGO, September 27, 2023 – Onchilles Pharma, a private biotech company developing new pan-cancer therapeutics that leverage a novel mechanism of action, announced today the presentation of preclinical data for the N17350 program at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention…

SAN DIEGO and ORLANDO, April 19, 2023 – Onchilles Pharma, a private biotech company developing novel cancer therapeutics that leverage myeloid biology, presented new preclinical data on N17350, a first-in-class biologic therapeutic inspired by ELANE, a protein found in neutrophils that is part of a newly discovered innate cancer-killing pathway. The data demonstrate N17350, as…

SAN DIEGO, March 14, 2023 – Onchilles Pharma, a private biotech company developing new cancer therapeutics that leverage myeloid biology, announced today the presentation of preclinical data for N17350 at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 at the Orange County Convention Center in Orlando,…

SAN DIEGO, December 12, 2022 – Onchilles Pharma, a private biotech company developing new cancer therapeutics to modulate myeloid biology, announced today the nomination of its first drug development candidate, N17350, a first-in-class biologic therapeutic that is designed to leverage the immunobiology of neutrophils, a key part in the innate immune system, against a wide…